我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
  h3 s3 s$ V$ h: j; L9 ]NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
3 y; X6 c* A: m3 x+ Author Affiliations

: J5 d  H4 }3 ~6 |2 d& \1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
( G# T4 s& C9 ?+ f2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 \; T2 f' I  U% r4 _& A/ J4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
" b, [+ g: o5 ~: m5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
4 j3 O2 ~# {1 |; F9 C6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
2 H- |- t7 ~. ?7Kinki University School of Medicine, Osaka 589-8511, Japan
6 T6 b1 R2 g7 N* ^8Izumi Municipal Hospital, Osaka 594-0071, Japan
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
* [! S. X: @. p+ D* ^- p& Z$ z+ sAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
! _3 V8 ~7 v- g, l7 y! i
" c* n/ y7 T' w9 N' Y3 c4 Q4 d

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
* h6 n: ?- {, e. [1 ]* {: S
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
& a  \! b0 ^4 B3 c8 [; I
5 v$ n7 X/ |0 Q0 P9 S. iAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
) K7 ?2 f6 N2 i0 K# X
  T% a" g3 m% _( h, T; LPublished online on: Thursday, December 1, 2011
/ T2 d5 W# p  u$ r0 {  l# I, H
Doi: 10.3892/ol.2011.507

Pages: 405-410
3 f7 H- f+ e& P
* G) ~7 \9 ^) C+ k0 |Abstract:
' S+ G7 `" z: w. S. Y# U+ tS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
( l- R* u9 i" q
6 x: o, C. x* y, y! N6 z

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
% O- i- Y- y9 r# J' [F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
+ Author Affiliations
; F. x3 c6 |4 |3 v8 C7 V& {* j  u* p1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
9 j. U3 h' _- Q; E4 }2Department of Thoracic Surgery, Kyoto University, Kyoto
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
* Z5 v! D% r, ]! g&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
% o' J: {* H/ S: lReceived September 3, 2010.
' V" g" g0 Y. a$ nRevision received November 11, 2010.
/ l- _3 L$ \$ A  U0 `' j$ [Accepted November 17, 2010.
8 o7 q4 F& D8 U3 F5 v  R4 _Abstract
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
9 B" S7 u+ d" W9 t" u3 V) QPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
8 v6 i9 D% Z" p' D

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
( j* s' R( e5 \  [0 k  o+ [- |http://clinicaltrials.gov/ct2/show/NCT01523587

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
8 H8 S2 S; Z2 h- vhttp://clinicaltrials.gov/ct2/show/NCT01156545

从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
: p) s8 Q' o7 j至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

                               
登录/注册后可看大图

从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
) c( [) i' a" Z至今为止，未出 ...

没有副作用是第一追求，效果显著是第二追求。
) d2 c4 _. B; U& I7 v$ a  n8 X9 W: Q不错。